Pages

Sunday, 9 May 2021

Philippines OKs Chinese drug Lianhua Qingwen, but not for COVID-19 treatment

In China, Lianhua Qingwen is used to treat mild to moderate cases of COVID-19.

12 Aug 2020


Metro Manila (CNN Philippines, August 12) — The Food and Drug Administration has approved a traditional Chinese medicine called Lianhua Qingwen, but not for COVID-19 treatment.

FDA Director General Eric Domingo told CNN Philippines on Wednesday that the drug should only be used as indicated in the Certificate of Product Registration, a copy of which was released by the Chinese Embassy in Manila.

It states that the Lianhua Qingwen capsule got the government’s greenlight on August 7 as a “traditionally used herbal product [that] helps remove heat-toxin invasion of the lungs, including symptoms such as fever, aversion to cold, muscle soreness, stuffy and runny nose.”

In China, Lianhua Qingwen is used to treat mild to moderate cases of COVID-19.

“It is our sincere hope that its entrance into the Philippine market will contribute to the fight against the spread of COVID-19 in this country and help the patients with mild and moderate symptoms recover,” the Chinese Embassy said in its statement.

It also welcomed the FDA’s move as an “important progress” in the entry of traditional Chinese medicines in the local market, noting that the Lianhua Qingwen is produced by one of its renowned manufacturers, Shijiazhuang Yiling Pharmaceutical Co. Ltd.

The embassy advised consumers to purchase products only from qualified pharmaceutical manufacturers.

Chinese Embassy Manila
about 9 months ago

The Chinese Embassy in the Philippines is glad to learn that the Philippine Food and Drug Administration (FDA) has approved Chinese drug #LianHuaQingWen produced by one of China’s renowned Traditional Chinese Medicine (#TCM) manufacturers, Shijiazhuang Yiling Pharmaceutical Co. Ltd., making the drug formally registered as TCM in the Philippines.👏👏👏

This marks an important progress in the entry of TCM products into the Philippine market, which we welcome.

Lianhua Qingwen Capsu...

See more
May be an image of text that says "Philippines DRUG Filinvest C Pursuant FDAI CERTIFICATE OF PRODUCT REGISTRATION described Registration Number THPR-50 requirements eig regulations infoeas Forsythia tandards datehereof. Weeping Honeysuck (Heartleaf Houttuynia Capsule Classification Helps Packaging rescription Aluminum exceeding Blister enclosed Importer Distributor Shijiazhuang harmaceutica Tianshan High-Tech Hebei China Archipelag International Limtuaco Shijiazhuang conditions commercial presentation Samson This should regulations subjecto formulation authorization approval subject suspension cancellation Authority 7August General 2016-005 JESUSA CIRUNAY, DirectorIV FDA FBAP FDA-0498408"
May be an image of 1 person
May be an image of text that says "YILING GYZZ Z20040063 Lianhua Qingwen Capsule Clear heat and detoxify, remove lung hotness. treatment epidemic influenza lung heat, symptom fever aversion muscular soreness, discharge, headache flushigtongue yellowo greasy throat, tongue. 350mg/capsule 24 Capsule Please see insertbefore SHIJIAZHUANG LING PHARMACEUTICAL co. LTD."
1.6K
386
2K

The coronavirus disease originated in Wuhan, China in December 2019, but the East Asian country now has fewer infections than 29 other states, including the Philippines. China has recorded 89,020 COVID-19 cases while the Philippines has more than 143,000.

https://cnnphilippines.com/news/2020/8/12/Philippines-FDA-approves-Chinese-drug-Lianhua-Qingwen-.html

ALSO: 

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lianhuaqingwencapscom-608667-07062020

https://www.fda.gov/consumers/health-fraud-scams/fraudulent-coronavirus-disease-2019-covid-19-products